Comparative Pharmacology
Head-to-head clinical analysis: AZSTARYS versus METHYLIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZSTARYS versus METHYLIN ER.
AZSTARYS vs METHYLIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
20-60 mg orally once daily in the morning
None Documented
None Documented
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant